A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
Recruiting now
Conditions studied: Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
In brief
Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers. The preliminary objective of this study is aimed at selecting PD-1+ and CTLA4+ T cells and other cellular fractions from peripheral blood of cancer patients and healthy volunteers by using specific conjugated antibodies, evaluating their functional ex vivo anti-tumor cytotoxicity against targeted autologous tumor cells.
Key facts
- Study ID
- NCT00571389
- Run by
- BioCytics, Inc.
- People needed
- 1500
- Starts
- 2007-11-01
- Expected to finish
- 2030-02-01
- Last updated by the study team
- 2026-03-18
Who can join
Age: 5 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Carolina BioOncology Institute — Huntersville, North Carolina, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.